Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Related Citations for PubMed (Select 23364217)

1.

Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.

Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M.

Chemotherapy. 2012;58(6):439-44. doi: 10.1159/000345920. Epub 2013 Jan 29.

PMID:
23364217
2.

[The efficacy of indisetron hydrochloride for the management of chemotherapy-induced nausea and vomiting for lung cancer].

Iritani E, Isono K, Izumo T, Takeda N, Kanemura T, Tamaoki J, Nagai A.

Gan To Kagaku Ryoho. 2009 Sep;36(9):1489-92. Japanese.

PMID:
19755818
3.

Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.

Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM.

Support Care Cancer. 2012 May;20(5):1043-7. doi: 10.1007/s00520-011-1180-2. Epub 2011 May 9.

PMID:
21553313
4.

[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].

Sato Y, Hayakawa Y, Tatematsu M, Muro K, Noma H, Okamoto H.

Gan To Kagaku Ryoho. 2012 Aug;39(8):1215-9. Japanese.

PMID:
22902445
5.

Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.

Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B.

Support Care Cancer. 2011 Dec;19(12):2063-6. doi: 10.1007/s00520-011-1286-6.

PMID:
21976035
6.

Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.

Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.

Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111/j.1445-5994.2011.02637.x.

PMID:
22141732
8.

Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 regimen: results of a prospective randomized crossover study.

Liu Y, Zhang J, Teng Y, Zhang L, Yu P, Jin B, Zhao M, Shi J, Liu S, Song N, Li Z.

Tumori. 2009 Nov-Dec;95(6):691-6.

PMID:
20210231
9.

Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).

Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer.

Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31.

PMID:
23392220
10.

Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.

Markman MR, Peterson G, Kulp B, Markman M.

Gynecol Oncol. 2002 Jun;85(3):435-7.

PMID:
12051870
11.

[Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].

Mori M, Kiba T, Oikawa M, Hokkoku K, Watanabe Y, Nakagawa T, Shintaku K, Yoshimitsu Y, Sakuma H, Ueda H, Nakai M.

Gan To Kagaku Ryoho. 2009 Feb;36(2):325-7. Japanese.

PMID:
19223757
12.

[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].

Abe T, Hachiro Y, Kunimoto M.

Gan To Kagaku Ryoho. 2010 Dec;37(13):2933-5. Japanese.

PMID:
21160274
13.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
14.

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M.

Support Care Cancer. 2011 Oct;19(10):1505-10. doi: 10.1007/s00520-010-0974-y. Epub 2010 Aug 8.

15.

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.

Aogi K, Sakai H, Yoshizawa H, Masuda N, Katakami N, Yanagita Y, Inoue K, Kuranami M, Mizutani M, Masuda N.

Support Care Cancer. 2012 Jul;20(7):1507-14. doi: 10.1007/s00520-011-1239-0. Epub 2011 Aug 2.

PMID:
21808994
17.

Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.

Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.

Ann Pharmacother. 2012 Dec;46(12):1637-44. doi: 10.1345/aph.1R396. Epub 2012 Nov 20.

PMID:
23170032
18.

[The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer].

Ushijima K, Wake N, Kobayashi H, Hachisuga T, Toki N, Masuzaki H, Kotera K, Kawarabayashi T, Emoto M, Kamura T.

Gan To Kagaku Ryoho. 2008 Jul;35(7):1169-73. Japanese.

PMID:
18633256
19.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
20.

Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.

dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP.

J Natl Cancer Inst. 2012 Sep 5;104(17):1280-92. doi: 10.1093/jnci/djs335. Epub 2012 Aug 21. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk